An Analysis of the Clinical Benefits of Hydroxyl Ag Titan Sheet (HATS) in 12 Adults with Hay Fever

摘要

Background / Objective: The prevalence of hay fever in Japan is a little over 40 percent. Effective treatments for hay fever have been sought in order to prevent not only decreases in affected individuals’ quality of life, but also labor losses and increases in healthcare costs. The purpose of this study is to verify the clinical efficacy of composite Hydroxyl Ag Titan Sheet (HATS), a new, proprietary treatment for hay fever, developed by adding silver to the photocatalytic effect of titanium oxide and by using hydroxyapatite. Research Method: The research subjects were seven women and five men, with an average age of 47.6 years. The method of the research was to compare each respective subject's time when not using the treatment to their time while using it. We verified the data by comparing the subjective clinical efficacy of both HATS not using and HATS using periods. Each period was 5 days. Specifically, additive-free non-woven fabric not treated with HATS were made into string shapes 1 cm wide x 5 cm and inserted intranasally for 40 minutes from 9:00 AM for five consecutive days henceforth, the HATS non-using group. Five days later, non-woven fabric containing henceforth HATS using group was used in the same manner as with the control group, and an evaluation was performed by comparing the therapeutic value, for each groups against hay fever symptoms before and after for each five day period. The institution carrying out the research was a medical institution in Tokyo. The research period was November 1~(st), 2015 to May 30~(th), 2016. Results: Both HATS using and HATS non-using group were compared for the sevirity of three symptoms; nasal inflammation sneezing, nasal mucus, nasal, and nasal obstruction. Sneezing was scored at 2.25, nasal mucus at 3.03 and nasal obstruction at 3.08. Improvements in symptoms were observed in the HATS using group compared with HATS non-using. The HATS using group showed significant improvement 24 hours after treatment. The value for sneezing went to 1.42, nasal mucus to 2.17, and nasal obstruction to 2.00. This effect was significant maintained throughout the five days compared with the HATS non-using group. Additionally, neither subjective nor clinical side effects were observed. Conclusions: There was no improvement in symptoms observed for the HATS non-using group during five day period. In the HATS using group, however, subjective and clinical improvement without any side effects were shown. In order to make practical use of HATS treatment as a simple home care therapeutic approach, there will be a need to verify the absence of side effects. Randomized, controlled intervention studies, along with research into long-term effects is needed.